Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
Provided By GlobeNewswire
Last update: Aug 25, 2025
ALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025.
Read more at globenewswire.com
